Novartis vs Roche: Strategic Comparison
Direct Answer
Roche is the larger company by market value, worth roughly $355 billion on September 21, 2026, compared with Novartis's roughly $275 billion, and Roche also has more employees (112,774 versus 75,267). Novartis is the more profitable operator on a margin basis for fiscal 2025: a net margin of about 25.6% ($13.984 billion of net income on $54.532 billion of net sales) versus Roche's roughly 22.4% (CHF 13.8 billion of net income on ~$73.8 billion (CHF 61.5 billion) of group sales). Novartis is a pure-play prescription-medicines company after spinning off Sandoz in 2023, while Roche also runs a ~$16.6 billion (CHF 13.8 billion) diagnostics division.
Novartis and Roche sit on opposite banks of the Rhine in Basel, and the two have a stranger history than most pharma rivals: in the early 2000s Novartis quietly built a stake of roughly one-third of Roche's voting shares in an unsuccessful attempt to force a merger, and did not sell that remaining stake back to Roche until 2021. Novartis traces its roots to the 1996 merger of Ciba-Geigy and Sandoz and has been led by CEO Vas Narasimhan since February 1, 2018; Roche was founded in 1896 by Fritz Hoffmann-La Roche and has been run by CEO Thomas Schinecker since March 2023. For fiscal 2025 (year ended December 31, 2025), Novartis reported $54.532 billion in net sales ($56.674 billion including other revenue) and net income of $13.984 billion on 75,267 employees, while Roche reported CHF 61.5 billion in group sales and ~$16.6 billion (CHF 13.8 billion) in net income on 112,774 employees. Despite Novartis posting the higher net margin, Roche's market value of roughly $355 billion on September 21, 2026 was well above Novartis's roughly $275 billion.
Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.
Key Differences at a Glance
| Field | Novartis AG | F. Hoffmann-La Roche AG |
|---|---|---|
| Latest annual revenue | $56.7B (FY2025) | ~$76B (FY2025) |
| Founded | 1996 | 1896 |
| Employees | 75,267 | 112,774 |
| Market Cap | $275.3B | $355.0B |
| Headquarters | Switzerland | Switzerland |
| Revenue / Employee | $753k / employee | $674k / employee |
| Valuation Multiple | 4.9x P/S | 4.7x P/S |
Strategic Positioning
Business model and competitive context from the cited profiles
Novartis AG Strategic Vector
FY2025 Revenue BaselineNovartis's corporate strategy centers on operating as a pure-play innovative medicines company dedicated to five technology platforms: chemistry, biotherapeutics, xRNA, radioligand therapy, and cell and gene therapy. Under Chief Executive Officer Vas Narasimhan, Novartis completed a multi-year corporate transformation—spinning off Alcon and Sandoz and divesting its stake in Roche for twenty billion dollars—sharpening organizational focus on high-value, high-margin patented medicines. In oncology, Novartis is expanding Pluvicto into earlier-stage prostate cancer while scaling Kisqali's reach in adjuvant early breast cancer (NATALEE trial). Concurrently, Novartis is expanding its radioligand manufacturing footprint in Indiana, New Jersey, and Spain, cementing an unassailable commercial infrastructure for targeted nuclear oncology.
F. Hoffmann-La Roche AG Strategic Vector
FY2025 Revenue BaselineRoche's long-term strategy focuses on overcoming biosimilar competition on legacy oncology blockbusters (Herceptin, Avastin, MabThera) by scaling breakthrough ophthalmology and neuroscience therapies while investing heavily in computational drug discovery and AI. Under Chief Executive Officer Thomas Schinecker, Roche is expanding Vabysmo—a bispecific antibody targeting both VEGF and Ang-2 for retinal vascular diseases—which has rapidly captured billions in market share from legacy treatments due to extended durability allowing patients to go four months between eye injections. In neuroscience, Ocrevus remains the standard of care in multiple sclerosis, while the company is advancing oral GLP-1 and dual incretin candidates acquired through Carmot Therapeutics to enter the cardiometabolic obesity arena.
Quick Stats Comparison
| Metric | Novartis AG | F. Hoffmann-La Roche AG |
|---|---|---|
| Revenue | $56.7B (FY2025) | ~$76B (FY2025) |
| Founded | 1996 | 1896 |
| Headquarters | Basel, Switzerland | Basel, Switzerland |
| Market Cap | $275.3B | $355.0B |
| Employees | 75,267 | 112,774 |
| Revenue / Employee | $753k / employee | $674k / employee |
| Valuation Multiple | 4.9x P/S | 4.7x P/S |
Novartis Revenue vs Roche Revenue — Year by Year
| Year | Novartis AG | F. Hoffmann-La Roche AG | Higher reported revenue |
|---|---|---|---|
| 2025 | $56.7B | ~$76B | F. Hoffmann-La Roche AG (approx. USD) |
| 2024 | $51.7B | ~$74.9B | F. Hoffmann-La Roche AG (approx. USD) |
| 2023 | $46.7B | ~$72.5B | F. Hoffmann-La Roche AG (approx. USD) |
| 2022 | $43.5B | ~$79B | F. Hoffmann-La Roche AG (approx. USD) |
| 2021 | $44.0B | ~$79B | F. Hoffmann-La Roche AG (approx. USD) |
Business Model Breakdown
Overview: Novartis AG vs F. Hoffmann-La Roche AG
This in-depth comparison examines Novartis AG and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and F. Hoffmann-La Roche AG is widest.
On the headline numbers, annual revenue is $56.7B (FY2025) for Novartis AG and ~$76B (FY2025) for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $275.3B and $355.0B. Both Novartis AG and F. Hoffmann-La Roche AG are headquartered in Switzerland. Their local markets and applicable rules may still differ.
Novartis AG: Novartis is one of the world's largest drugmakers by sales and the larger of Basel's two pharmaceutical groups alongside Roche. Created by the 1996 merger of Ciba-Geigy and Sandoz, it shed eye care (Alcon, 2019) and generics (Sandoz, 2023) and now sells only innovative medicines. Its best-known products include Entresto for heart failure, Cosentyx for psoriasis and arthritis, Kisqali for breast cancer, Kesimpta for multiple sclerosis and Pluvicto for prostate cancer. The company is headquartered in Basel, Switzerland.
F. Hoffmann-La Roche AG: Roche Holding AG is a Swiss healthcare company headquartered in Basel and listed on the SIX Swiss Exchange (ROG non-voting equity securities and RO bearer shares; RHHBY ADRs in the US). It is one of the largest pharmaceutical companies by sales and the largest in vitro diagnostics supplier. Key subsidiaries include Genentech in the US, Chugai Pharmaceutical in Japan and Foundation Medicine. The company is headquartered in Basel, Switzerland.
Business Models: How Novartis AG and F. Hoffmann-La Roche AG Make Money
Novartis AG and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and F. Hoffmann-La Roche AG.
Novartis AG business model: Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology. Following the strategic spin-off of its generic and biosimilar division (Sandoz) and consumer eye-care business (Alcon), Novartis operates as a pure-play, high-margin biopharmaceutical enterprise. Its revenue model is powered by targeted biologics, small molecules, and advanced technology platforms including radioligand therapies (RLTs), cell and gene therapies, and xRNA therapeutics. Flagship blockbusters include Entresto (sacubitril/valsartan for heart failure), Cosentyx (secukinumab for psoriasis and ankylosing spondylitis), Kesimpta (ofatumumab for multiple sclerosis), Pluvicto (radioligand for prostate cancer), and Kisqali (ribociclib for HR+/HER2- breast cancer).
F. Hoffmann-La Roche AG business model: F. Hoffmann-La Roche AG (Roche Group) is a Swiss multinational healthcare pioneer that operates an integrated model combining targeted pharmaceuticals with in-vitro medical diagnostics. The company functions through two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops innovative medicines in oncology (Perjeta, Kadcyla, Phesgo for HER2-positive breast cancer; Tecentriq for immunotherapy; Alecensa), immunology (Actemra), ophthalmology (Vabysmo for wet macular degeneration), and neuroscience (Ocrevus for multiple sclerosis, Evrysdi for spinal muscular atrophy). The Diagnostics division engineers automated clinical laboratory instruments, molecular PCR diagnostics, tissue pathology testing, and point-of-care monitoring systems for clinical laboratories, research hospitals, and commercial diagnostics centers worldwide.
Competitive Advantage: Novartis AG vs F. Hoffmann-La Roche AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of F. Hoffmann-La Roche AG.
Novartis AG competitive advantage: Novartis's economic moat is anchored by its pioneering leadership in advanced technology platforms—specifically radioligand therapies and gene therapy manufacturing—and Entresto's entrenched global standard-of-care position in heart failure. In radioligand therapies, Novartis constructed a proprietary global radioisotope supply chain (producing lutetium-177 therapies Pluvicto and Lutathera) that requires specialized nuclear particle accelerators, cyclotrons, and precision short-half-life logistics that generic competitors cannot replicate. In cardiovascular medicine, Entresto is prescribed to millions of heart failure patients worldwide, generating robust multi-billion-dollar cash flows supported by extensive guideline recommendations. Kesimpta provides an easily self-administered targeted B-cell subcutaneous injection for multiple sclerosis, giving Novartis high patient retention in neurology.
F. Hoffmann-La Roche AG competitive advantage: Roche's durable competitive moat is underpinned by the synergistic union of in-vitro diagnostics and targeted biopharmaceuticals, creating the global benchmark for personalized healthcare. By developing companion diagnostic tests that identify specific genetic mutations or biomarkers in patient tissue samples, Roche pairs its diagnostic assays directly with its targeted therapies, ensuring high clinical adoption and hospital laboratory lock-in. Roche holds the number one market share in global in-vitro diagnostics and tissue pathology, with thousands of automated Cobas lab analyzers installed in commercial laboratories worldwide that generate recurring, high-margin diagnostic reagent sales. In pharmaceuticals, Roche's biotechnology subsidiary Genentech provides an elite scientific research engine that has produced some of the most influential monoclonal antibodies in medical history.
Growth Strategy: Where Novartis AG and F. Hoffmann-La Roche AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and F. Hoffmann-La Roche AG each plan to expand from here.
Novartis AG growth strategy: Novartis concentrates on four therapeutic areas and on the US, its largest market. It pairs internal research with bolt-on acquisitions of late-stage or platform biotechs: Chinook (2023, kidney disease), MorphoSys (2024, myelofibrosis), Kate Therapeutics (2024, gene therapy capsids) and Avidity Biosciences (closed February 27, 2026, about $12 billion, neuromuscular RNA medicines). It is also expanding US manufacturing, including radioligand production capacity.
F. Hoffmann-La Roche AG growth strategy: Roche is building a cardiovascular, renal and metabolic franchise through acquisitions of Carmot Therapeutics (2023, $2.7 billion upfront) and 89bio (2025, up to about $3.5 billion), the petrelintide partnership with Zealand Pharma, and a new Innovation Center in Boston opened in September 2026. It is also extending its immunology pipeline via Telavant (2023, $7.1 billion) and investing in AI diagnostics with the PathAI acquisition announced in May 2026 ($750 million upfront plus up to $300 million in milestones).
Financial Picture: Novartis AG vs F. Hoffmann-La Roche AG
A closer look at the financial trajectory of Novartis AG and F. Hoffmann-La Roche AG rounds out the comparison.
Novartis AG: Novartis grew FY2025 net sales 8% to $54.5 billion with a core operating margin above 40% and free cash flow of $17.6 billion. 2026 is a reset year: US generics of Entresto and Promacta cut Q1 2026 net sales 5% at constant currencies to $13.1 billion and core operating income 14%. Q2 2026 net sales rose 1% cc to $14.4 billion with a 41.2% core margin, though net income fell 19%. Management guides for low single-digit sales growth and a low single-digit decline in core operating income for 2026 at constant currencies. Novartis is a Swiss multinational pharmaceutical corporation with a market valuation generally exceeding $200 billion.
F. Hoffmann-La Roche AG: Roche's 2025 group sales were ~$73.8 billion (CHF 61.5 billion), up 7% at constant exchange rates but only 2% in Swiss francs. Core operating profit grew 13% CER to ~$26.2 billion (CHF 21.8 billion), core EPS was CHF 19.46, and IFRS net income jumped to ~$16.6 billion (CHF 13.8 billion) from ~$11 billion (CHF 9.2 billion) in 2024, when impairments depressed profit. In H1 2026 core operating margin widened 1.7 points to 39.0%, while a strong franc pushed reported sales down 2%. The board raised the dividend to CHF 9.80, the 39th consecutive increase, and guided for mid-single-digit CER sales growth and high-single-digit core EPS growth in 2026. F. Hoffmann-La Roche AG is a colossal Swiss multinational healthcare company operating heavily under two massive divisions: Pharmaceuticals and Diagnostics, sustaining a market valuation generally exceeding $250 billion.
Company-Specific SWOT Notes
Novartis AG
Novartis operates an extensive portfolio of patent-protected specialty therapeutics, radioligand therapies, and cardiovascular medicines generating strong recurring revenues.
Proprietary nuclear particle supply chains for Pluvicto and Lutathera establish Novartis as the undisputed pioneer in precision radioligand therapies for metastatic oncology.
Loss of patent exclusivity on legacy blockbuster drugs creates periodic revenue headwind, requiring continuous clinical pipeline replenishment.
Impending patent challenges and generic entry for its multi-billion-dollar heart failure medication Entresto create revenue replacement pressure on the clinical pipeline.
Investing in next-generation radioligand cancer therapies and cell therapies positions Novartis to address unmet oncology medical needs with premium pricing.
Government-mandated drug price negotiation frameworks in the United States and healthcare cost containment policies in Europe pressure pharmaceutical gross margins.
F. Hoffmann-La Roche AG
~$57.2B (CHF 47.7B) in pharma sales and ~$16.6B (CHF 13.8B) in diagnostics sales in 2025, with companion tests that support drug adoption.
The Hoffmann and Oeri family pool holds the majority of voting shares, supporting long-horizon R&D.
H1 2026 sales grew 6% at constant rates but fell 2% in CHF because of franc appreciation.
Loss of exclusivity on legacy biological blockbusters (Rituxan, Herceptin, Avastin) requires continuous pipeline commercialization to maintain top-line growth.
Enicepatide, petrelintide, pegozafermin (89bio) and PathAI give Roche new growth options beyond oncology.
High late-stage clinical development costs combined with government healthcare cost-containment measures in the US and Europe pressure biopharmaceutical pricing.
Factual Scorecard
| Category | Result | Why |
|---|---|---|
| Same-period Revenue Scale | F. Hoffmann-La Roche AG | $56.7B (FY2025) versus ~$76B (FY2025); the higher figure is identified after approximate USD conversion. |
| Founded Earlier | F. Hoffmann-La Roche AG | Novartis AG was founded in 1996; F. Hoffmann-La Roche AG was founded in 1896. |
Comparison Takeaway: Novartis vs Roche
Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.
Frequently Asked Questions: Novartis vs Roche
Is Novartis bigger than Roche in 2026?
It depends on the measure. Roche is bigger by group sales (~$73.8 billion (CHF 61.5 billion) in FY2025) and by market value (about $355 billion on September 21, 2026), and has nearly 1.5 times the headcount (112,774 versus 75,267). Novartis is bigger by net profit margin (about 25.6% versus Roche's roughly 22.4% in FY2025) and reports its results in US dollars rather than Swiss francs, so its $54.532 billion of FY2025 net sales needs no currency conversion for US comparisons.
Which is more profitable, Novartis or Roche?
Novartis had the higher net margin in fiscal 2025, at about 25.6% ($13.984 billion of net income on $54.532 billion of net sales), compared with Roche's roughly 22.4% (CHF 13.8 billion of net income on ~$73.8 billion (CHF 61.5 billion) of group sales). Roche's net income grew faster in percentage terms, though, jumping to ~$16.6 billion (CHF 13.8 billion) from ~$11 billion (CHF 9.2 billion) in FY2024, when impairment charges had depressed the prior year's result.
Who runs Novartis and who is Roche's CEO?
Vas Narasimhan has been Novartis's CEO since February 1, 2018, becoming one of the youngest leaders of a major drugmaker at age 41. Thomas Schinecker has led Roche since March 2023, when he succeeded Severin Schwan, who had run Roche for 14 years and then became its chairman.
Did Novartis ever try to buy Roche?
Yes. In the early 2000s Novartis built up roughly one-third of Roche's voting shares in an unsuccessful attempt to force a merger between the two Basel rivals. Novartis held onto that minority stake for nearly two decades before finally selling it back to Roche in 2021, ending one of pharma's longest-running ownership standoffs.
Which is the better pharma stock, Novartis or Roche?
Neither wins on every measure. Novartis has the stronger net margin (about 25.6% versus roughly 22.4% in FY2025) and a focused, pure-play medicines portfolio, while Roche is larger by market value (about $355 billion versus Novartis's roughly $275 billion on September 21, 2026) and more diversified, with a ~$16.6 billion (CHF 13.8 billion) diagnostics division and a 39-year streak of consecutive dividend increases through 2025.
Which company was founded first, Novartis AG or F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG was founded in 1896; Novartis AG was founded in 1996.
What revenue did Novartis AG and F. Hoffmann-La Roche AG report?
Novartis AG had $56.7B (FY2025), while F. Hoffmann-La Roche AG had ~$76B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.
How do Novartis AG and F. Hoffmann-La Roche AG make money?
Novartis AG: Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology. F. Hoffmann-La Roche AG: F.
Which is better, Novartis AG or F. Hoffmann-La Roche AG?
There is no evidence-based single winner. Compare Novartis AG and F. Hoffmann-La Roche AG on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.
Sources & References
- Novartis AG Corporate Website
- Novartis AG 2025 revenue figure: Novartis AG Form 20-F for fiscal year 2025 (net sales from continuing operations plus other revenues)
- novartis.com
- en.wikipedia.org
- novartis.com
- novartis.com
- stockanalysis.com
- wsj.com
- novartis.com
- novartis.com
- novartis.com
- fiercebiotech.com
- F. Hoffmann-La Roche AG Corporate Website
- F. Hoffmann-La Roche AG 2025 revenue figure: Roche Holding AG (SWX:ROP) annual reports, as compiled by S&P Global (via StockAnalysis)
- roche.com
- roche.com
- roche.com
- roche.com
- assets.roche.com
- roche.com
- stockanalysis.com
- assets.roche.com
Quick Answer
Roche is the larger company by market value, worth roughly $355 billion on September 21, 2026, compared with Novartis's roughly $275 billion, and Roche also has more employees (112,774 versus 75,267). Novartis is the more profitable operator on a margin basis for fiscal 2025: a net margin of about 25.6% ($13.984 billion of net income on $54.532 billion of net sales) versus Roche's roughly 22.4% (CHF 13.8 billion of net income on ~$73.8 billion (CHF 61.5 billion) of group sales). Novartis is a pure-play prescription-medicines company after spinning off Sandoz in 2023, while Roche also runs a ~$16.6 billion (CHF 13.8 billion) diagnostics division.
Verdict
Novartis and Roche compete head-on in oncology, immunology and neuroscience, but their business models have diverged: Novartis became a pure-play innovative-medicines company after spinning off Sandoz in 2023, while Roche kept a ~$16.6 billion (CHF 13.8 billion) diagnostics arm that earns recurring revenue from lab instruments, reagents and companion tests tied to its own drugs. Novartis is the more profitable operator on net margin (about 25.6% versus Roche's roughly 22.4% in fiscal 2025) and grew net sales 8% that year, but it is also carrying more near-term pipeline risk: its roughly $12 billion acquisition of Avidity Biosciences, completed February 27, 2026, saw its lead program miss the Phase 3 HARBOR trial in September 2026. Roche has leaned toward steady compounding instead, raising its dividend for a 39th consecutive year in 2025 to CHF 9.80 per share while adding obesity and AI-diagnostics optionality through its 89bio and PathAI deals. The market currently rewards Roche's diversification and dividend record with the bigger valuation, about $355 billion versus Novartis's $275 billion, even though Novartis posts the better margin.
Cite This Page
Automatically generated citations for researchers.
CorpDigest. (2026). Novartis AG vs F. Hoffmann-La Roche AG Comparison. from https://corpdigest.com/compare/novartis-vs-roche
CorpDigest. "Novartis AG vs F. Hoffmann-La Roche AG Comparison." CorpDigest, 2026, https://corpdigest.com/compare/novartis-vs-roche.
CorpDigest. "Novartis AG vs F. Hoffmann-La Roche AG Comparison." CorpDigest. 2026. https://corpdigest.com/compare/novartis-vs-roche.